Kate Levenberg*, Wade Edris, Martha Levine and Daniel R. George Pages 1 - 6 ( 6 )
Epidemiologic studies suggest that the lifetime prevalence of bipolar spectrum disorders range from 2.8 to 6.5 percent of the population. To decrease morbidity and mortality associated with disease progression, pharmacologic intervention is indicated for the majority of these patients. While a number of effective treatment regimens exist, many conventional medications have significant side effect profiles that adversely impact patients’ short and long-term wellbeing. It is thus important to continue advancing therapeutic options available to patients. This paper reviews the limitations of current treatments and examines the chemical compound Linalool, an alcohol found in many plant species, that may serve as an effective mood stabilizer. While relatively little is known about Linalool and bipolar disorder, the compound has been shown to have anti-epileptic, anti-inflammatory, anxiolytic, anti-depressive, and neurotrophic effects, with mechanisms that are comparable to current bipolar disorder treatment options.
Bipolar disorder, linalool, neurotherapeutics, anti-epileptic, drug development, plant based medicine
College of Medicine, Penn State University College of Medicine, State College, Department of Medicine, Penn State University College of Medicine, State College, Department of Pediatrics, Penn State University College of Medicine, Hershey, Department of Pediatrics, Penn State University College of Medicine, Hershey